Integrative oncology—the best from one world Jutta Hübner Editorial Open access 01 July 2022 Pages: 3225 - 3226
A novel endoplasmic reticulum stress-related lncRNA prognostic risk model for cutaneous melanoma An-an LiFan LiMei-ying Yan Original Article – Cancer Research 10 June 2022 Pages: 3227 - 3241
Blocking autophagy with chloroquine aggravates lipid accumulation and reduces intracellular energy synthesis in hepatocellular carcinoma cells, both contributing to its anti-proliferative effect Fengming XuHans-Michael TautenhahnUta Dahmen Original Article – Cancer Research Open access 13 June 2022 Pages: 3243 - 3256
Aberrant MEK5 signalling promotes clear cell renal cell carcinoma development via mTOR activation Fangzhou LiXufeng PengYonghui Chen Original Article – Cancer Research 17 June 2022 Pages: 3257 - 3266
Single-cell transcriptional profiling reveals heterogeneity and developmental trajectories of Ewing sarcoma Bo HongYi LiRui Dong Original Article – Cancer Research 17 June 2022 Pages: 3267 - 3280
Inhibition of angiogenesis and tumor progression of MK-0429, an integrin αvβ3 antagonist, on oral squamous cell carcinoma Takayuki NakagawaKouji OhtaTomonao Aikawa Original Article – Cancer Research Open access 17 June 2022 Pages: 3281 - 3292
CFTR reduces the proliferation of lung adenocarcinoma and is a strong predictor of survival in both smokers and non-smokers Qingyang XiaoStefania KoutsilieriVolker M. Lauschke Original Article – Cancer Research Open access 17 June 2022 Pages: 3293 - 3302
Influencing factors of lung cancer patients' participation in shared decision-making: a cross-sectional study Ying WangJinna ZhangXiuli Zhu Original Article – Cancer Research 18 June 2022 Pages: 3303 - 3312
Prognostic significance of MATR3 in stage I and II non-small cell lung cancer patients Justyna DurślewiczAnna Klimaszewska-WiśniewskaMarcin Braun Original Article – Cancer Research 20 June 2022 Pages: 3313 - 3322
Blood group antigens SLeX, SLeA, and LeY as prognostic markers in endometrial cancer Thomas KolbenLena MüllerSusanne Beyer Original Article – Cancer Research Open access 21 June 2022 Pages: 3323 - 3335
Optimization of whole-cell vaccines with CpG/αOX40/cGAMP to strengthen the anti-tumor response of CD4+ T cells in melanomas Xuedan DuJinting WuWenfeng Li Original Article – Cancer Research Open access 24 June 2022 Pages: 3337 - 3350
Apalutamide and autophagy inhibition in a xenograft mouse model of human prostate cancer Daniel EberliBenedikt KranzbühlerSouzan Salemi Original Article – Cancer Research Open access 25 June 2022 Pages: 3351 - 3360
Synergistic antitumor effect of a penicillin derivative combined with thapsigargin in melanoma cells Yanina BellizziPatricia G. CornierLeonor P. Roguin Original Article – Cancer Research 25 June 2022 Pages: 3361 - 3373
N6-methyladenosine (m6A) reader IGF2BP2 stabilizes HK2 stability to accelerate the Warburg effect of oral squamous cell carcinoma progression Ke XuXiaojuan DaiKai Wen Original Article – Cancer Research 28 June 2022 Pages: 3375 - 3384
Co-expression of DDR2 and IFITM1 promotes breast cancer cell proliferation, migration and invasion and inhibits apoptosis Chenlu WuJiafei YingDanhua Zhang Original Article – Cancer Research 28 June 2022 Pages: 3385 - 3398
The hyaluronan-related genes HAS2, HYAL1-4, PH20 and HYALP1 are associated with prognosis, cell viability and spheroid formation capacity in ovarian cancer Jette RiecksArianna ParnigoniMartin Götte Original Article – Cancer Research Open access 29 June 2022 Pages: 3399 - 3419
T helper cell-mediated epitranscriptomic regulation via m6A RNA methylation bridges link between coronary artery disease and invasive ductal carcinoma Sudeshna RakshitJithin S. SunnyKoustav Sarkar Original Article – Cancer Research 01 July 2022 Pages: 3421 - 3436
Prognostic impact of the number of peri-tumoral alveolar macrophages in patients with stage I lung adenocarcinoma Osamu NoritakeKeiju AokageGenichiro Ishii Original Article – Cancer Research 02 July 2022 Pages: 3437 - 3447
The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphoma Zhenchang SunWenjuan WanMingzhi Zhang Original Article – Cancer Research 20 July 2022 Pages: 3449 - 3459
Clinical and sociodemographic determinants of disease-specific health-related quality of life in long-term breast cancer survivors Daniela DoegeMelissa S. Y. ThongVolker Arndt Original Article – Cancer Research Open access 25 July 2022 Pages: 3461 - 3473
Overexpression of splicing factor poly(rC)-binding protein 1 elicits cycle arrest, apoptosis induction, and p73 splicing in human cervical carcinoma cells Yuhong ChenZhihui DouCuixia Di Original Article – Cancer Research 27 July 2022 Pages: 3475 - 3484
Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression Shengshu LiXiaoxin LuFang Li Original Article – Cancer Research 30 July 2022 Pages: 3485 - 3499
Modelling reoxygenation effects in non-small cell lung cancer cell lines and showing epithelial-mesenchymal transition Joanna KapelerisJuliana Müller BarkChamindie Punyadeera Original Article – Cancer Research Open access 06 August 2022 Pages: 3501 - 3510
Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs Xiaokang ZhangShishuo SunQing Zhang Original Article – Cancer Research 12 August 2022 Pages: 3511 - 3520
Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trapping Subhajit ChatterjeeAjit Kumar DhalChanakya Nath Kundu Original Article – Cancer Research 13 August 2022 Pages: 3521 - 3535
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study Emre YekedüzDeniz TuralYüksel Ürün Original Article – Clinical Oncology 26 May 2022 Pages: 3537 - 3546
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group Mustafa GürbüzYasin KutluAhmet Demirkazık Original Article – Clinical Oncology 11 June 2022 Pages: 3547 - 3555
PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy Yixiang ZhuYe ZhangYutao Liu Research 20 July 2022 Pages: 3557 - 3566